Azenta, Inc. (AZTA) — Quarterly Report

AI-Powered SEC Filing Analysis

Latest Quarterly Report Filed: 2026-05-08

Key Insights

The filing shows a Q2 2026 period ending March 31, 2026, with multiple restatement adjustments and prior period error corrections indicated in the XBRL data, suggesting accounting adjustments that require investor attention.
The company is actively managing discontinued operations related to the B Medical Systems Business (held for sale as of December 23, 2025), which will impact comparative financial metrics and segment reporting going forward.
The presence of Edwards Vacuum LLC warranty claim adjustments and UK Biocentre transaction elements (dated March 4, 2026) indicate ongoing legal/operational matters that could affect financial results and require monitoring for resolution.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-05

Azenta, Inc. (AZTA) reported solid financial performance in Q1 2026, with revenue of $4,053 million and EPS of $0.01, both in line with expectations.
The company's Core Products and Services segments continued to deliver stable results, indicating strong demand for their automated storage, cryogenic systems, and sample management offerings.
Azenta has incurred transformation costs related to strategic initiatives aimed at streamlining operations and improving long-term productivity, which may impact near-term profitability but could yield benefits in the future.

Other reports for Azenta, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.